

## Technology Advisory Committee B Interests Register

### Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]

Publication Date: 11/12/2024

| Name                 | Role with NICE | Type of interest     | Description of interest  | Interest declared        | Comments   |
|----------------------|----------------|----------------------|--|--------------------------|--|
| Peter Wheatley Price | TAC B Member   | Direct               | Takeda manufacture ixazomib which is used in combination with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505). They have just successfully exited the CDF (ID1635). We are also in process to evaluate usage in frontline. | 08/02/2024               | It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.      |
| Veline L'Esperance   | TAC B Member   | Indirect - Financial | Employer received funding from GSK regarding shingles vaccination uptake. Veline is the PI on the project.   | 14/03/2024               | It was agreed that Veline's declaration would not prevent her from participating in discussions on this appraisal. |
| Scott Purdon         | Patient Expert | Indirect – Financial | We have received funding for a specific research project from the manufacturer of the technology in the last 12 months (£19,259). 2022. In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849).  | 09/10/2024<br>14/03/2024 | It was agreed that Scott's declaration would not prevent him from providing expert advice to the committee.        |

| Name        | Role with NICE  | Type of interest      | Description of interest   | Interest declared        | Comments   |
|-------------|-----------------|-----------------------|---|--------------------------|--|
| Jon Missin  | Patient expert  | Indirect – Financial  | We have received funding for a specific research project from the manufacturer of the technology in the last 12 months (£19,259). 2022. In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849). | 09/10/2024<br>14/03/2024 | It was agreed that Jon's declaration would not prevent him from providing expert advice to the committee.    |
| Gordon Cook | Clinical expert | Direct - Professional | Consultancy – BMS/Celgene, Takeda, Janssen, Sanofi, Roche, Amgen, Pfizer, Abbvie<br><br>Indirect - Research Funding – BMS/Celgene, Takeda, Janssen  | 09/10/2024<br>14/03/2024 | It was agreed that Gordon's declaration would not prevent him from providing expert advice to the committee. |